First Trust Health Care AlphaDEX (FXH)

First Trust Health Care AlphaDEX (FXH) is an exchange-traded fund that holds a concentrated portfolio of large-cap healthcare companies selected using the AlphaDEX formula, which combines value and growth metrics to identify stocks trading at attractive relative valuations within the sector.

Healthcare represents roughly one-sixth of the U.S. economy, but not all healthcare stocks attract the same kind of investor. Many healthcare ETFs cast a broad net across pharmaceutical giants, medical-device makers, hospital operators, health insurers, and biotech firms. FXH operates differently: it homes in on large companies that AlphaDEX, a proprietary methodology developed by First Trust and NASDAQ, identifies as undervalued relative to their earnings, cash flow, and growth prospects. The fund competes not just against generic healthcare indices but against other factor-tilted healthcare vehicles that apply different screening criteria.

The healthcare sector is economically dense. Pharmaceutical companies benefit from patent moats and recurring revenue from blockbuster drugs, but face pricing pressure from governments and insurers and the looming cliff when patents expire. Medical-device makers operate in a world of regulatory approval, hospital buying committees, and persistent margin pressure from consolidation on the buyer side. Health insurers navigate complex reimbursement incentives and regulatory constraints. Hospital operators swing between profitable cycles and margin squeezes depending on utilization and labor costs. A fund that wants to do well in healthcare must pick firms positioned to manage these distinct dynamics — not just buy the sector broad.

AlphaDEX applies a two-stage screening process. First, it ranks stocks within the NASDAQ Healthcare Index by value and growth metrics — primarily price-to-earnings, price-to-book, price-to-sales, and earnings revision momentum. Second, it weights the selected stocks using the Alpha approach, which emphasizes recent changes in analyst sentiment and earnings revisions. The outcome is a portfolio that tilts toward names showing both undervaluation and positive earnings revisions, a signal that the market may have priced in too much pessimism. The fund typically holds 30–40 stocks, making it more concentrated than a broad healthcare index.

FXH’s sector focus shapes its holdings heavily. Large pharmaceutical firms — the companies that spend billions on research and command pricing power through patent protection — make up a meaningful portion. Medical-device leaders, which supply hospitals and health systems with equipment, diagnostics, and monitoring tools, represent another bloc. Health insurers, which profit by managing the flow of capital through the system, appear as well. Providers (hospital operators and large physician groups) have appeared in varying weights as the fund’s methodology identifies opportunities. The fund avoids the edges of healthcare — pure biotech plays, emerging medical-device startups, and specialized diagnostic firms — in favor of established firms with large market capitalizations and liquid markets.

The expense ratio is modest by active-tilting standards, typical of First Trust’s AlphaDEX lineup. Like all AlphaDEX funds, FXH rebalances quarterly, which creates some turnover and tax consequences but keeps the portfolio aligned to the methodology. The fund is liquid, trading in volume heavy enough that tight bid-ask spreads are common. It is suitable for investors who want healthcare exposure but prefer a systematic selection method over broad-market equal-weighting or market-cap weighting.

Healthcare funds face two persistent challenges that shape their returns. The first is regulatory risk: any major change in drug pricing, reimbursement, or healthcare access can ripple through the entire sector unpredictably. The second is the heterogeneity of the sector itself — pharma and medical devices and insurers respond to different economic and policy signals, so a “healthcare fund” is really a basket of several related but distinct businesses. FXH’s concentration on large-cap value tilts it toward firms with established pricing power and recurring revenue, but that also means it may miss rallies in higher-growth therapeutic areas or emerging players reshaping healthcare delivery.

For a reader researching FXH, the prospectus and fact sheet are the essential documents, available from First Trust’s website. The fund’s holdings are published daily. Understanding the approach means reading about the AlphaDEX methodology and tracking how the quarterly rebalance changes the composition. Healthcare investors should also pay attention to the underlying 10-K filings of the largest holdings — particularly large pharmaceutical firms’ patent expiration schedules, medical-device makers’ reimbursement environment, and insurers’ claims ratios — because these fundamentals drive the sector’s long-term returns far more than the selection methodology does.